Novo Nordisk shares were under pressure on Monday as the struggling Danish pharmaceutical said a head-to-head study found a drug in development didn't cut as much weight as an Eli Lilly product.
Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly's in trial CNBCNovo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial ReutersNovo Nordisk Stock Plunges and Eli Lilly Jumps. It's Because of This Weight-Loss Drug Trial. Barron'sNovo Nordisk Trial Flop Ripples Through Denmark's Stock Market Bloomberg
The push-off hurt, but Kentucky's mistakes hurt more On3Freeman's tip-in, Murphy's career night give Auburn win over Kentucky Auburn TigersMark Pope recaps gut punch at Auburn A Sea Of BlueOweh's Career High Not Enough as Kentucky Falls at Auburn UK AthleticsMark Pope says officials 'cheated' Kentucky in hot-mic moment after foul call in last-second loss to
TSA says PreCheck still operational after previous announcement of suspension during funding fight WTOPDHS reverses course on suspending TSA PreCheck after outcry The Washington PostTSA says PreCheck still operational after announcement saying otherwise Los Angeles TimesHomeland Security to Shut TSA PreCheck and Global Entry at Airports The New York Times